In a mouse model of melanoma, after apigenin treatment, DCs were incubated with cytokine-induced killer (CIK) cells, resulting in CIK cells showing robust immunity in a melanoma cell killing assay, indicating that apigenin enhances T cell immunity by limiting the expression of PD-L1 in DCs51. This evidence concerns the gene CD274 and melanoma.